Shilpa Medicare receives Cofepris GMP certificate, Mexico for Ambroxol, Nifedipine and Gemcitabine :: IndiaNivesh

Please Share::

�� India Equity Research Reports, IPO and Stock News Visit http://indiaer.blogspot.com/ for complete details ��

Shilpa Medicare Ltd.|Q2FY15 Result Update | CMP : Rs.557 | Rating : HOLD | Target : Rs.473 | A muted quarter; however, levers for future growth remain in place :: IndiaNivesh

Please Share::

�� India Equity Research Reports, IPO and Stock News Visit http://indiaer.blogspot.com/ for complete details ��